Centessa Pharmaceuticals (CNTA) Expected to Announce Quarterly Earnings on Monday

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) is projected to announce its Q1 2025 earnings results before the market opens on Monday, May 12th. Analysts expect the company to announce earnings of ($0.35) per share for the quarter.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last posted its quarterly earnings results on Monday, March 24th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.38) by $0.04. On average, analysts expect Centessa Pharmaceuticals to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Centessa Pharmaceuticals Trading Up 0.8 %

NASDAQ CNTA opened at $13.61 on Monday. The company has a market cap of $1.81 billion, a PE ratio of -8.90 and a beta of 1.53. Centessa Pharmaceuticals has a 12 month low of $7.75 and a 12 month high of $19.09. The stock has a 50 day moving average of $14.17 and a 200-day moving average of $15.78. The company has a current ratio of 21.52, a quick ratio of 21.52 and a debt-to-equity ratio of 0.15.

Insider Activity

In related news, insider Karen M. Anderson sold 30,526 shares of the business's stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $19.03, for a total value of $580,909.78. Following the completion of the sale, the insider now directly owns 54,322 shares in the company, valued at approximately $1,033,747.66. The trade was a 35.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock in a transaction on Thursday, February 20th. The shares were sold at an average price of $15.93, for a total value of $876,150.00. Following the completion of the transaction, the chief executive officer now directly owns 331,017 shares of the company's stock, valued at $5,273,100.81. This represents a 14.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 202,353 shares of company stock valued at $3,286,478. 11.59% of the stock is owned by company insiders.

Analyst Ratings Changes

Several research analysts have recently weighed in on CNTA shares. Guggenheim restated a "buy" rating and set a $28.00 price objective on shares of Centessa Pharmaceuticals in a research note on Wednesday, March 26th. Piper Sandler began coverage on Centessa Pharmaceuticals in a research note on Monday, March 31st. They set an "overweight" rating and a $38.00 target price for the company. TD Cowen started coverage on Centessa Pharmaceuticals in a report on Tuesday, January 7th. They set a "buy" rating on the stock. Finally, Morgan Stanley reaffirmed an "overweight" rating and set a $27.00 price target on shares of Centessa Pharmaceuticals in a report on Friday, March 7th. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $27.71.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.